Trevi Therapeutics, Inc. (NASDAQ:TRVI) Morgan Stanley twenty third Annual World Healthcare Convention September 9, 2025 4:05 PM EDT
Firm Members
Jennifer Good – Co-Founder, CEO, President, Interim Principal Monetary Officer & Director
Farrell Simon – Chief Industrial Officer
Convention Name Members
Judah Frommer – Morgan Stanley, Analysis Division
Presentation
Judah Frommer
Fairness Analyst
Welcome to this session of the Morgan Stanley World Healthcare Convention. I am excited to welcome the crew from Trevi.
Earlier than I do this, let me learn a fast disclosure assertion. For vital disclosures, please see the Morgan Stanley analysis disclosure web site at www.morganstanley.com/researchdisclosures. When you’ve got any questions, please attain out to your Morgan Stanley gross sales consultant.
So with that, Jennifer, Farrell, thanks for being right here.
Query-and-Reply Session
Judah Frommer
Morgan Stanley, Analysis Division
Perhaps we might simply begin with an summary of the corporate for many who is perhaps much less acquainted, or newer to the story? That might be nice.
Jennifer Good
Co-Founder, CEO, President, Interim Principal Monetary Officer & Director
Sure, joyful to do this. And thanks to everybody that got here. I see some previous buddies within the viewers. And Judah, thanks to you and Morgan Stanley, our latest relationship, latest analyst. That is nice.
So Trevi has had a powerful 12 months. We’re a single-asset firm. We have now a drug that is broadly within the opioid class however is in a subcategory of combined agonist-antagonist. We’ll in all probability speak extra about that. What’s attention-grabbing about it’s you get the advantages of opioids, good efficacy, good security with out the habit potential. So the drug has been round. It has been unscheduled. So we will get extra into that later.
However what’s distinctive about that mechanism is it really works each centrally and peripherally. So I am one of many two cofounders of the corporate. I co-founded it with the neurologist. Tom, my
